Who are Interferon beta 1a, oral doxycycline's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/interferon-beta-1a-oral-doxycycline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Interferon beta 1a, oral doxycycline — Competitive Intelligence Brief

Interferon beta 1a, oral doxycycline (Interferon beta 1a, oral doxycycline) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine + tetracycline antibiotic combination. Area: Immunology / Infectious Disease.

marketed Cytokine + tetracycline antibiotic combination Interferon-beta receptor (IFNBR); doxycycline targets bacterial ribosomes and matrix metalloproteinases Immunology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Interferon beta 1a, oral doxycycline (Interferon beta 1a, oral doxycycline) — Louisiana State University Health Sciences Center Shreveport. Interferon beta-1a enhances immune response against viral infections and autoimmune disease, while oral doxycycline provides broad-spectrum antibiotic and anti-inflammatory effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Interferon beta 1a, oral doxycycline TARGET	Interferon beta 1a, oral doxycycline	Louisiana State University Health Sciences Center Shreveport	marketed	Cytokine + tetracycline antibiotic combination	Interferon-beta receptor (IFNBR); doxycycline targets bacterial ribosomes and matrix metalloproteinases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine + tetracycline antibiotic combination class)

Louisiana State University Health Sciences Center Shreveport · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Interferon beta 1a, oral doxycycline — Competitive Intelligence Brief. https://druglandscape.com/ci/interferon-beta-1a-oral-doxycycline. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab